Latest (62) Full Text Articles (1570) Focus on Liver Article Summary

Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: A phase IIb trial
Gastroenterology, 01/24/2014  Clinical Article

Zeuzem S, et al. – The authors performed a phase IIb, randomized, double–blind, placebo–controlled trial to evaluate the efficacy and safety of the combination of simeprevir, peginterferon–α2a (PegIFN), and ribavirin (RBV) in patients with hepatitis C virus (HCV) genotype–1 infection previously treated with PegIFN and RBV. In treatment–experienced patients, 12, 24, or 48 weeks simeprevir (100 mg or 150 mg once daily) in combination with 48 weeks PegIFN and RBV significantly increased rates of SVR at 24 weeks compared with patients given placebo, PegIFN, and RBV and was generally well tolerated.

Methods

  • The authors analyzed data from patients who did not respond (null response), had a partial response, or relapsed after treatment with PegIFN and RBV, randomly assigned to receive simeprevir (100 or 150 mg, once daily) for 12, 24, or 48 weeks plus PegIFN and RBV for 48 weeks (n = 396), or placebo plus PegIFN and RBV for 48 weeks (n = 66).
  • All patients were followed for 24 weeks after planned end of treatment; the primary end point was the proportion of patients with sustained virologic response (SVR; undetectable HCV RNA) at that time point.

Results

  • Overall, rates of SVR at 24 weeks were significantly higher in the groups given simeprevir than those given placebo (61%-80% vs 23%; P < .001), regardless of prior response to PegIFN and RBV (simeprevir vs placebo: prior null response, 38%-59% vs 19%; prior partial response, 48%-86% vs 9%; prior relapse, 77%-89% vs 37%).
  • All groups had comparable numbers of adverse events; these led to discontinuation of simeprevir or placebo and/or PegIFN and RBV in 8.8% of patients given simeprevir and 4.5% of those given placebo.

► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Gastroenterology

See All >> Messages include industry-sponsored communications and special communications from PDR - powered by MDLinx

Most Popular Gastroenterology Articles

Last month's top read Top Articles of 2014

1 Screening prior to biological therapy in Crohn's disease: Adherence to guidelines and prevalence of infections. Results from a multicentre retrospective study Digestive and Liver Diseases, August 4, 2014    Clinical Article

2 A prospective, randomized, controlled, exploratory study of comprehensive dietary advice in ulcerative colitis: impact on disease activity and quality of life European Journal of Gastroenterology & Hepatology, July 10, 2014    Clinical Article

3 Fecal lactoferrin in discriminating inflammatory bowel disease from irritable bowel syndrome: A diagnostic meta-analysis Full Text BMC Gastroenterology, July 14, 2014    Free full text    Evidence Based Medicine

4 Bolus administration of steroid therapy is more favorable than the conventional use in preventing decrease of bone density and the increase of body fat percentage in patients with inflammatory bowel disease Journal of Crohn's and Colitis, August 22, 2014    Clinical Article

5 The impact of preoperative steroid use on short-term outcomes following surgery for inflammatory bowel disease Journal of Crohn's and Colitis, August 8, 2014    Clinical Article

6 Prognostic effect of p53 expression in patients with completely resected colorectal cancer Tumor Biology, July 18, 2014    Clinical Article

7 Proton pump inhibitor use significantly increases the risk of spontaneous bacterial peritonitis in 1965 patients with cirrhosis and ascites: a propensity score matched cohort study Alimentary Pharmacology and Therapeutics, August 1, 2014    Clinical Article

8 Risk of drug-induced liver injury from tumor necrosis factor antagonists Clinical Gastroenterology and Hepatology , August 25, 2014    Clinical Article

9 Inflammatory bowel disease and cervical neoplasia: a population-based nationwide cohort study Clinical Gastroenterology and Hepatology , August 14, 2014    Clinical Article

10 Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: A randomized, double-blind, placebo-controlled study Journal of Crohn's and Colitis, August 27, 2014    Clinical Article

11 Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis Clinical Gastroenterology and Hepatology , June 25, 2014    Evidence Based Medicine    Clinical Article

12 Magnetic resonance enterography, small-intestine contrast US, and capsule endoscopy to evaluate the small bowel in pediatric Crohn's disease: A prospective, blinded, comparison study Gastrointestinal Endoscopy, August 18, 2014    Clinical Article

13 The vitamin D status in inflammatory bowel disease PLOS ONE, July 18, 2014    Clinical Article
Exclusive Author Commentary

14 Moxibustion and acupuncture for the treatment of Crohn’s disease Full Text World Journal of Gastroenterology, August 29, 2014    Free full text    Clinical Article

15 Once versus three times daily dosing of oral budesonide for active Crohn's disease: A double-blind, double-dummy, randomised trial Journal of Crohn's and Colitis, August 28, 2014    Clinical Article

16 Comparing omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors: Double-blind placebo-controlled trial Neurogastroenterology & Motility, February 10, 2014    Clinical Article

17 An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis Clinical Gastroenterology and Hepatology , August 6, 2014    Clinical Article

18 Increased risk of venous thromboembolic events with corticosteroid vs biologic therapy for inflammatory bowel disease Clinical Gastroenterology and Hepatology , July 25, 2014    Clinical Article

19 Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease Alimentary Pharmacology and Therapeutics, July 3, 2014    Clinical Article

20 Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease-The McGill experience Journal of Crohn's and Colitis, July 9, 2014    Clinical Article

Indexed Journals in Gastroenterology: Gastroenterology, American Journal of Gastroenterology, Gutmore

Other Topics in Gastroenterology

Register now to view all our site's content (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from our site and our sponsors
View Samples and Register